Great Valley Advisor Group’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$678K Buy
11,174
+426
+4% +$24.8K 0.01% 595
2025
Q4
$580K Buy
10,748
+551
+5% +$26.5K 0.01% 592
2025
Q3
$460K Sell
10,197
-22,745
-69% -$1.06M 0.01% 645
2025
Q2
$1.52M Sell
32,942
-2,434
-7% -$119K 0.03% 369
2025
Q1
$2.16M Buy
35,376
+1,173
+3% +$68.4K 0.05% 300
2024
Q4
$1.93M Sell
34,203
-767
-2% -$42.9K 0.04% 325
2024
Q3
$1.81M Buy
34,970
+3,471
+11% +$163K 0.04% 324
2024
Q2
$1.31M Sell
31,499
-61,339
-66% -$2.74M 0.04% 341
2024
Q1
$5.03M Buy
92,838
+46,527
+100% +$2.37M 0.15% 147
2023
Q4
$2.38M Buy
46,311
+30,734
+197% +$1.61M 0.08% 217
2023
Q3
$904K Sell
15,577
-1,313
-8% -$80.5K 0.04% 332
2023
Q2
$1.08M Sell
16,890
-538
-3% -$36.1K 0.05% 304
2023
Q1
$1.21M Buy
17,428
+1,399
+9% +$98.7K 0.06% 283
2022
Q4
$1.15M Buy
16,029
+1,341
+9% +$101K 0.06% 305
2022
Q3
$1.04M Sell
14,688
-1,694
-10% -$123K 0.06% 300
2022
Q2
$1.26M Buy
16,382
+8,823
+117% +$672K 0.07% 271
2022
Q1
$537K Buy
7,559
+526
+7% +$35.3K 0.03% 368
2021
Q4
$435K Sell
7,033
-478
-6% -$28K 0.03% 413
2021
Q3
$445K Sell
7,511
-620
-8% -$40.8K 0.03% 388
2021
Q2
$537K Sell
8,131
-50
-0.6% -$3.26K 0.04% 335
2021
Q1
$517K Sell
8,181
-167
-2% -$10.4K 0.05% 297
2020
Q4
$518K Buy
8,348
+337
+4% +$20.7K 0.05% 273
2020
Q3
$483K Buy
8,011
+663
+9% +$39.9K 0.06% 254
2020
Q2
$432K Sell
7,348
-100
-1% -$5.98K 0.07% 255
2020
Q1
$415K Sell
7,448
-14
-0.2% -$856 0.11% 196
2019
Q4
$479K Buy
7,462
+2,906
+64% +$166K 0.11% 208
2019
Q3
$231K Buy
4,556
+9
+0.2% +$423 0.06% 307
2019
Q2
$207K Buy
+4,547
New +$212K 0.05% 317

Other funds holding BMY

Great Valley Advisor Group's BMY Position: Q1 2026 in Review

Great Valley Advisor Group increased its Bristol-Myers Squibb (BMY) stake by 4% in Q1 2026, buying an estimated $24.8K and bringing the position to 11,174 shares worth $678K. The position accounts for 0.01% of the portfolio, ranked #595.

Great Valley Advisor Group first reported a position in BMY in Q2 2019 and has held it in 28 quarters since. The position peaked at $5.03M in Q1 2024. 2,520 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Great Valley Advisor Group held 11,174 shares of Bristol-Myers Squibb worth $678K as of Q1 2026.
  • Great Valley Advisor Group bought 426 Bristol-Myers Squibb shares in Q1 2026, an estimated $24.8K.
  • Bristol-Myers Squibb made up 0.01% of Great Valley Advisor Group's portfolio in Q1 2026, its #595 holding.
  • Great Valley Advisor Group first reported a position in Bristol-Myers Squibb in Q2 2019 and has held it in 28 quarters since.
  • Great Valley Advisor Group's Bristol-Myers Squibb position peaked at $5.03M in Q1 2024.
  • 2,520 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Great Valley Advisor Group's 13F filing for Q1 2026, filed 11 May 2026.